- Home
- TYGO vs TLSI Comparison
TYGO vs TLSI Comparison
Compare TYGO & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TYGO | TLSI |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | 110 |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.4M | 267.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TYGO | TLSI |
|---|---|---|
| Price | $3.75 | $4.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 425.7K | 194.6K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.12 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $103,536,000.00 | N/A |
| Revenue This Year | $30.78 | $36.47 |
| Revenue Next Year | $21.68 | $39.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.68 | N/A |
| 52 Week Low | $0.58 | $3.42 |
| 52 Week High | $4.57 | $7.95 |
Technical Indicators
Market Signals| Indicator | TYGO | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 48.83 |
| Support Level | $3.19 | $3.79 |
| Resistance Level | $4.33 | $5.33 |
| Average True Range (ATR) | 0.43 | 0.24 |
| MACD | -0.06 | 0.06 |
| Stochastic Oscillator | 33.20 | 80.52 |
Price Performance
Historical ComparisonAbout TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.